Abstract:Our findings provide a novel and effective combination strategy for increasing potent anthelmintic agent avermectin B1a production by enhancing supplies of both acyl‐CoA starter and extender units. We achieved significant increase of B1a titer in Streptomyces avermitilis WT and industrial strains by heterologous expression of assembled loading module‐extension module 7‐TE domain of meilingmycin polyketide synthase, inhibition of key nodes in FA synthesis and TCA cycle pathways using CRISPRi, and co‐overexpression of β‐oxidation pathway genes fadD and fadAB for increasing levels of 2‐methylbutyryl‐CoA, malonyl‐CoA, and methylmalonyl‐CoA precursors. Such precursor supply strategies can be readily adapted for overproduction of other polyketides. Avermectins (AVEs), a family of macrocyclic polyketides produced by Streptomyces avermitilis, have eight components, among which B1a is noted for its strong insecticidal activity. Biosynthesis of AVE "a" components requires 2‐methylbutyryl‐CoA (MBCoA) as starter unit, and malonyl‐CoA (MalCoA) and methylmalonyl‐CoA (MMCoA) as extender units. We describe here a novel strategy for increasing B1a production by enhancing acyl‐CoA precursor supply. First, we engineered meilingmycin (MEI) polyketide synthase (PKS) for increasing MBCoA precursor supply. The loading module (using acetyl‐CoA as substrate), extension module 7 (using MMCoA as substrate) and TE domain of MEI PKS were assembled to produce 2‐methylbutyrate, providing the starter unit for B1a production. Heterologous expression of the newly designed PKS (termed Mei‐PKS) in S. avermitilis wild‐type (WT) strain increased MBCoA level, leading to B1a titer 262.2 μg/mL – 4.36‐fold higher than WT value (48.9 μg/mL). Next, we separately inhibited three key nodes in essential pathways using CRISPRi to increase MalCoA and MMCoA levels in WT. The resulting strains all showed increased B1a titer. Combined inhibition of these key nodes in Mei‐PKS expression strain increased B1a titer to 341.9 μg/mL. Overexpression of fatty acid β‐oxidation pathway genes in the strain further increased B1a titer to 452.8 μg/mL – 8.25‐fold higher than WT value. Finally, we applied our precursor supply strategies to high‐yield industrial strain A229. The strategies, in combination, led to B1a titer 8836.4 μg/mL – 37.8% higher than parental A229 value. These findings provide an effective combination strategy for increasing AVE B1a production in WT and industrial S. avermitilis strains, and our precursor supply strategies can be readily adapted for overproduction of other polyketides.

The Mutasynthetic Production of CHC-B1 from a Streptomyces Avermitilis Mutant in the Presence of Cyclohexanecarboxylic Acid.

Screening the Fusarium Graminearum Inhibitory Mutant Strain from Bacillus Subtilis by Atmospheric-Pressure Plasma Jet

Multisite Mutation of the Escherichia Coli Camp Receptor Protein: Enhancing Xylitol Biosynthesis by Activating Xylose Catabolism and Improving Strain Tolerance.

Strain-screening in biotransformation of d-pseudoephedrine and expression of its bcdh gene

Improvement of Cephalosporin C Production by Recombinant DNA Integration in Acremonium Chrysogenum

Enhancement of acyl‐CoA precursor supply for increased avermectin B1a production by engineering meilingmycin polyketide synthase and key primary metabolic pathway genes

Mutation breeding of high avermectin B1a-producing strain by the combination of high energy carbon heavy ion irradiation and sodium nitrite mutagenesis based on high throughput screening

60Co Γ-Irradiation MUTATION INDUCTION FOR SCREENING OF AVILAMYCIN STRAINS WITH HIGH PRODUCTIVITY AND ITS CULTURE MEDIUM OPTIMIZATION

Reverse Biological Engineering Of Hrdb To Enhance The Production Of Avermectins In An Industrial Strain Of Streptomyces Avermitilis

Direct Proteomic Mapping of Streptomyces Avermitilis Wild and Industrial Strain and Insights into Avermectin Production

Acyltransferase Domain Swapping for the Production of Tenvermectin B Metabolites in Genetically Engineered Strain Streptomyces avermitilis HU02

Avermectin B1a production in Streptomyces avermitilis is enhanced by engineering aveC and precursor supply genes

Fermentation Products of AV-m-481, A Mutant Strain of Streptomyces Avermitilis

Blocking the flow of propionate into TCA cycle through a mutB knockout leads to a significant increase of erythromycin production by an industrial strain of Saccharopolyspora erythraea

Production of polyhydroxyalkanoates by Escherichia coli mutants with defected mixed acid fermentation pathways

Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A

Streptomyces Avermitilis Industrial Strain As Cell Factory for Ivermectin B1a Production.

Enhanced amphotericin B production by genetically engineered Streptomyces nodosus

Microbial Production of Cis-1,2-dihydroxy-cyclohexa-3,5-diene-1-carboxylate by Genetically Modified Pseudomonas Putida.

Submerged fermentation of Streptomyces uncialis providing a biotechnology platform for uncialamycin biosynthesis, engineering, and production

Enhancement of fungichromin production of Streptomyces sp. WP-1 by genetic engineering